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Abstract
Backgound: Shiga toxin 2 (Stx2), one of two Stx liberated by Stx-producing Escherichia coli, is composed of an A
subunit monomer and a B subunit pentamer, and is directly linked with hemolytic uremic syndrome in children.
The pentameric B subunit binds to its cell surface receptor Gb3 for toxin internalization, and the A subunit follows
intracellular retrograde transport to the cytosol where its RNA N-glycosidase activity (RNA-NGA) shuts down the
protein synthesis, and leads to cell death. The present study investigated the ability of 19 Stx2 A subunit-specific
human monoclonal antibodies (HuMAbs) to neutralize the RNA-NGA, and the association this neutralizing activity
with protection of HeLa cells and mice against Stx2-induced death.
Results: The HuMAbs that were stronger inhibitors of RNA-NGA were also better at neutralizing Stx2 mediated
HeLa cell death, and those that were weaker inhibitors of RNA-NGA activity were also weaker in protecting HeLa
cells. These results suggest that the ability of an A subunit-specific antibody to block the RNA-NGA of the toxin is
directly related to its ability to neutralize Stx2-mediated HeLa cell death. However, with the exception of the best
RNA-NGA blocking antibodies 5C12 and 2F10, the efficacies of antibody neutralization of RNA-NGA of Stx2 did not
correlate with their in vivo protective efficacies. The HuMAb 6C3, which neutralized RNA N-glycosidase activity of
Stx2 less effectively than the HuMAbs 6D8 and 6B7, protected 100% of the mice against Stx2 challenge at 50 μg/
mouse dose. In contrast, the HuMAbs 6D8 and 6B7, which neutralized RNA N-glycosidase activity of Stx2 more
effectively than 6C3, protected 20% and 0% mice at that dose, respectively.
Conclusions: The neutralization efficiency of the RNA-NGA of Stx2 by A subunit-specific antibodies correlate
strongly with their abilities to protect HeLa cells against Stx2-mediated toxicity but only the strongest RNA-NGA-
neutralizing antibodies correlate very well with both protecting HeLa cells and mice against Stx2 challenge.
Background
Infection with Shiga toxin (Stx)-producing Escherichia
coli (STEC) is the most significant cause of hemolytic
uremic syndrome (HUS), the leading cause of acute
renal failure in children [1-4]. Two antigenically distinct
Stx, Stx1 and Stx2, are associated with the development
of HUS. Stx1 and Stx2 are similar in basic structure [5],
binding specificity [5] and mode of action, but quite dis-
tinct in disease outcome [6]. Stx2-producing strains are
more frequently associated with HUS in humans than
Stx1- or both Stx1- and Stx2-producing strains [7,8].
The Stx molecule consists of an A-subunit monomer
and a B-subunit pentamer [5,9,10]. The pentameric B
subunit binds to its cell surface receptor CD77, also
called globotriaosyl ceramide (Gb3; Gala1-4Galb1-4glu-
cosyl ceramide) [11,12] with the exception of Stx2e,
which binds preferentially to globotetraosylceramide
(Gb4; GalNAc b1-3Gala1-4Galb1-4glucosyl ceramide)
[13,14]. Internalized Stx is then delivered to the trans-
Golgi network (TGN), where it is carried by retrograde
transport to the endoplasmic reticulum (ER), and then
to the cytosol [15,16]. During this process, the A subu-
nit is nicked by the membrane bound furin protease,
generating a catalytically active N-terminal A1 fragment
and a C-terminal A2 fragment; both fragments remain
linked by a disulphide bond [15,17]. The disulphide
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bond is subsequently reduced, and the active A1 compo-
nent is released. The released A1 fragment has N-glyco-
sidase catalytic activity and removes a specific adenine
base from the 28S rRNA of the 60S ribosomal subunit
[18,19]. Because this adenine base is on a loop of rRNA
that is important for elongation factor binding, the toxin
is able to shut down the protein synthesis and cause cell
death.
We have recently produced human monoclonal anti-
bodies (HuMAbs) against Stx1 and Stx2, and evaluated
them in animal models for their efficacy against sys-
temic challenge with the toxins [20,21]. We selected for
further analysis 5C12, a Stx2 A subunit-specific
HuMAb, based on its superior efficacy over others in
protecting mice against lethal challenge with Stx2 and
Stx2 variants [22]. Preclinical evaluation in a piglet
model of infection has shown that 5C12 protects piglets
against Stx2-induced fatal neurological symptoms, even
when the antibody is administered well after onset of
diarrhea and oral STEC challenge (48 hours post-chal-
lenge) [23]. In this model, diarrheal symptoms precede
systemic complications associated with Stx2 uptake
from the gut, as is observed in children.
The aim of the present study was to investigate
whether 5C12 and other A subunit specific HuMAbs
neutralize the RNA N-glycosidase activity (RNA-NGA)
of the toxin, and to assess whether this inhibitory activ-
ity is indicative of an antibody’s ability to neutralize Stx2
toxicity in vitro or in vivo.
Results
Grouping of the HuMAbs based on their strength to
neutralize Stx2-mediated HeLa cell cytotoxicity
Overall, HuMAbs showed a dose-dependent neutraliza-
tion of Stx2 (20 ng/ml), with maximum neutralization
occurring at the highest antibody concentration of 10
μg/ml (Table 1). Based on the Stx2-neutralizing activity,
the 19 HuMAbs analyzed in this study were assigned to
high, medium or low neutralizing groups. The neutraliz-
ing activity mostly differed significantly between the
antibodies of the three groups (Table 1). The HuMAbs
2F10, 3E9 and 5C12 neutralized Stx2-mediated HeLa
cell cytotoxicity significantly better than all other antibo-
dies, and therefore, were grouped as high neutralizing
antibodies. They neutralized 89%-97% of the Stx2
induced HeLa cell cytotoxicity at the highest antibody
Table 1 Neutralization of Stx2-mediated HeLa cell cytotoxicity by Stx2 A subunit-specific HuMAbs.
Neutralization groups1 HuMAb Percent neutralization (mean ± SD) at different HuMAb doses
10 μg/ml 1.25 μg/ml 0.156 μg/ml
High 5C12 97 ± 1.7a 89 ± 4.1a 73 ± 5.1a
3E9 94 ± 3.3ab 80 ± 6.5ab 52 ± 5.3ab
2F10 89 ± 4.6b 71 ± 7.6b 50 ± 4.2b
Medium 7C4 69 ± 6.5c 52 ± 6.2c 38 ± 4.1c
6D8 68 ± 9.6c 48 ± 8.5c 38 ± 3.2c
9H9 65 ± 10.6c 48 ± 7.4c 29 ± 5.9cd
6H7 64 ± 7.1c 46 ± 6.5c 22 ± 4.5d
14C12 63 ± 6.8c 39 ± 7.4cd 29 ± 8.8cd
5E12 59 ± 9.0cd 36 ± 6.4cd 17 ± 4.6de
6B7 57 ± 6.2cd 37 ± 5.5cd 23 ± 3.6d
6H5 57 ± 5.9cd 39 ± 3.5cd 25 ± 3.9d
6C3 50 ± 7.1de 37 ± 5.1cd 16 ± 3.6de
1G1 46 ± 7.3de 27 ± 7.5d 15 ± 1.9de
Low 4H10 40 ± 8.5ef 13 ± 5.3e 10 ± 5.3e
5F2 35 ± 4.7f 13 ± 5.5e 1 ± 0.7f
6E6 34 ± 5.6f 25 ± 6.1d 9 ± 4.6e
3A2 31 ± 8.1fg 15 ± 8.1e 14 ± 9.1de
7F2 25 ± 4.7g 14 ± 7.8e 7 ± 5.1e
1G12 15 ± 4.7h 11 ± 5.9e 10 ± 5.5e
Placebo control IgG1 5 ± 3.8h 5 ± 1.7e 2 ± 1.5f
1The HuMAbs were assigned to high (5C12, 3E9 and 2F10), medium (7C4, 6D8, 9H9, 6H7, 14C12, 5E12, 6B7, 6H5, 6C3 and 1G1) or low (4H10, 5F2, 6E6, 3A2, 7F2
and 1G12) neutralizing groups based on their abilities to neutralize Stx2-mediated HeLa cell cytotoxicity.
a-hValues within a column with different superscripts are significantly (P < 0.05) different.
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concentration of 10 μg/ml. HuMAb 5C12 was especially
potent since it neutralized about 90% toxicity of Stx2
even at 1.25 μg/ml. The Stx2-neutralizing activity of the
medium neutralizing group (6H5, 6H7, 7C4, 9H9,
14C12, 5E12, 6D8, 6B7, 6C3, and 1G1) was lower than
the high neutralizing group since it neutralized 45%-70%
of Stx2-mediated HeLa cell cytotoxicity at the highest
antibody concentration. The low neutralizing group
included the remaining six HuMAbs (4H10, 6E6, 1G12,
3A2, 5F2, and 7F2) which showed minimal to mild
toxin neutralization (<45%) even at the highest antibody
concentration.
Neutralization of RNA-NGA of Stx2 by the HuMAbs
The strongest Stx2-cytotoxicity neutralizing HuMAbs
2F10, 3E9, and 5C12 were also the strongest in blocking
the RNA-NGA of Stx2 (Fig. 1). Visual inspection (Fig.
1A and 1C) and semi-quantitative densitometry analysis
(Fig. 1B and 1D) of the Western blot bands showed that
the amount of luciferase produced in the presence of
these antibodies was closer to that translated in the
absence of Stx2. The quantitative expression of the luci-
ferase band in presence of the HuMAbs 2F10, 3E9, and
5C12 relative to when Stx2 was absent was 0.85, 0.92
and 0.99, respectively (Fig. 1B). The luciferase band ana-
lysis also revealed that the neutralization of RNA-NGA
of Stx2 by 7 (6H5, 6H7, 7C4, 14C12, 5E12, 6D8 and
6B7) of the 10 medium Stx2-cytotoxicity neutralizing
group antibodies was moderate (relative expression of
the luciferase bands between 0.60 - 0.80). The expres-
sion of the luciferase bands in presence of other 3 anti-
bodies (9H9, 6C3 and 1G1) of the medium Stx2-
cytotoxicity neutralizing group was weaker (relative
expression of the luciferase bands between 0.40 - 0.60)
than the other antibodies of this group but still better
than that of the low Stx2-cytotoxicity neutralizing group
antibodies. The expression of the luciferase bands in
presence of the low Stx2-cytotoxicity neutralizing group
antibodies (4H10, 6E6, 1G12, 3A2, 5F2, and 7F2) was
very weak (relative expression of the luciferase bands
<0.40). Overall, the strength by which the HuMAbs neu-
tralized RNA-NGA of Stx2 correlated with their
strength to neutralize Stx2-mediated HeLa cell cytotoxi-
city (Fig. 1).
To validate the differences observed in luciferase
translation (Fig. 1) in the presence of a single antibody
dose between high and the medium Stx2-cytotoxicity
neutralizing antibodies, dose response studies were per-
formed utilizing 5C12 from the high neutralizing group
and 6D8 and 6B7 from the medium neutralizing group
(Fig. 2). The neutralizing activity of these antibodies was
analyzed at different doses in the RNA N-glycosidase
assay in the presence of 10 ng of Stx2. The superiority
of 5C12 over 6D8 and 6B7 to neutralize RNA-NGA of
Stx2 was apparent at all doses, especially at the lower
doses of 93.7 and 46.8 ng (Fig. 2). At the 46.8 ng dose,
the quantitative expression of the luciferase band in
presence of the 5C12, 6D8 and 6B7 relative to when
Stx2 was absent was 0.72, 0.37 and 0.44, respectively
(Fig. 2B).
The dose response studies were also performed with
the HuMAbs 2F10, 3E9, and 5C12 to determine the best
RNA-NGA-neutralizing antibody (Fig. 3). The relative
band intensities, especially at the doses of 46.8 ng and
23.4 ng, show that the intensities of the luciferase bands
obtained with 2F10 and 3E9 were clearly lower than
that of 5C12. This suggests that the neutralization of
RNA-NGA by 5C12 was stronger than the other two
antibodies.
Neutralization of Stx2-induced mouse toxicity
by the HuMAbs
The 19 HuMAbs utilized in this study have been evalu-
ated before with the mouse toxicity model [20]. How-
ever, dose response studies were not performed (except
for 5C12, 2F10 and 3E9), and antibodies produced in
mouse ascites quantified by ELISA were used, as
opposed to protein A-purified antibodies quantified by
UV spectrophotometry used in the present study. Dose
response studies were required in the present study to
compare the relationship between neutralization of
RNA-NGA of Stx2 and protection in vivo against Stx2
challenge. The dose response studies were performed on
a few selected antibodies. The selection of these antibo-
dies was based on their neutralizing activities in the
RNA N-glycosidase assay. The HuMAbs 5C12 and 2F10
(strong or best RNA-NGA neutralizing antibodies), and
6D8 and 6B7 (moderate RNA-NGA neutralizing anti-
body), were selected. In addition, the HuMAb 6C3 was
included since it had lesser RNA-NGA neutralizing
activity than 6D8 and 6B7 (results of the present study),
but protected mice against Stx2 challenge [20]. We eval-
uated the antibodies’ activity in mice at the doses of 50
(3.5 mg/kg body weight) and 5 μg (350 μg/kg) per
mouse.
At 50 μg dose, 5C12, 2F10 and 6C3 completely pro-
tected mice against Stx2-mediated toxicosis and death
(Fig. 4). At the same dose, the antibodies 6B7 and 6D8
protected 0% and 20% mice, respectively. The protection
provided by 6D8 was barely significant (p = 0.04) to that
provided by PBS. The HuMAbs 5C12, 2F10 and 6C3
provided significantly better protection than 6D8
(p = 0.01), 6B7 (p = 0.002) and PBS (p = 0.002). All mice
in the PBS control group succumbed to Stx2 toxicity.
At the low dose of 5 μg, 5C12 was highly protective
since it protected all mice, and 2F10 was moderately
protective since it protected 60% of mice (Fig. 4), and
they did not differ significantly from each other. The
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Figure 1 Neutralization of the RNA-NGA of Stx2 by the A subunit-specific antibodies. The letters ‘H’, ‘M’ or ‘L’ within parenthesis after a
HuMAb designation represent high, medium or low HeLa cell cytotoxicity-neutralization groups of the antibodies, respectively. The HuMAbs
2F10, 3E9, and 5C12 were the strongest in blocking the RNA-NGA of Stx2 since visual inspection (Fig. 1A and 1C) and semi-quantitative
densitometry analysis (Fig. 1B and 1D) of the luciferase bands showed that the amount of produced in the presence of these antibodies was
similar to that translated in the absence of Stx2 ("no Stx2” lane). The luciferase band analysis also revealed that the neutralization of RNA-NGA of
Stx2 by medium Stx2-cytotoxicity neutralizing group antibodies 6H5, 6H7, 7C4, 14C12, 5E12, 6D8 and 6B7 was moderate since relative expression
of the luciferase bands was between 0.60 - 0.80. The expression of the luciferase bands in presence of the other 3 antibodies (9H9, 6C3 and
1G1) of the medium Stx2-cytotoxicity neutralizing group was weaker (relative expression of the luciferase bands between 0.40 - 0.60) than the
other antibodies of this group but still better than that of the low Stx2-cytotoxicity neutralizing group antibodies. The expression of the
luciferase bands in presence of the low Stx2-cytotoxicity neutralizing group antibodies (4H10, 6E6, 1G12, 3A2, 5F2, and 7F2) was very weak
(relative expression of the luciferase bands <0.40). The experiment was repeated once with similar results.
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Figure 2 Dose-dependent neutralization of the RNA-NGA of Stx2 by antibodies of high and medium HeLa cell cytotoxicity
neutralization groups. The letters ‘H’ or ‘M’ within parenthesis after a HuMAb designation represent high or medium HeLa cell cytotoxicity-
neutralization group/s of the antibodies, respectively. The superiority of 5C12 over 6D8 and 6B7 to neutralize RNA-NGA of Stx2 was apparent at
all doses, especially at the lower doses of 93.7 and 46.8 ng. At the 46.8 ng dose, the quantitative expression of the luciferase band in presence
of the 5C12, 6D8 and 6B7 relative to when Stx2 was absent was 0.72, 0.37 and 0.44, respectively. The experiment was repeated once with similar
results.
Figure 3 Dose-dependent Neutralization of the RNA-NGA of Stx2 by the best HeLa cell cytotoxicity- and RNA-NGA-neutralizing
HuMAbs 2F10, 3E9 and 5C12. The differences in neutralizing efficiency were certainly apparent at the lower doses of 46.8 ng and 23.4 ng. At
46.8 ng dose, the quantitative expression of luciferase band in presence of 2F10, 3E9 and 5C12 relative to when Stx2 was absent was 0.68, 0.65
and 0.81, respectively. At 23.4 ng dose, the relative expression of luciferase band in presence of 2F10, 3E9 and 5C12 was 0.54, 0.51 and 0.70. The
experiment was repeated once with similar results.
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HuMAb 5C12 provided significantly better protection
than 6C3 (p = 0.01), 6D8 (p = 0.002), 6B7 (p = 0.002)
and PBS (p = 0.002). The protection provided by 2F10
was significantly better than 6D8 (p = 0.003), 6B7 (p =
0.003) and PBS (p = 0.003) but not significantly better
than 6C3 (p = 0.2). Nonetheless, 2F10 protected 2.5
times more mice than 6C3. The antibody 6C3 showed
low level protection (protected 20% of mice) which was
significantly better than PBS (p = 0.01). The antibodies
6B7 and 6D8 failed to protect any mouse.
Discussion
In the present study, we have demonstrated that ability
of an A subunit-specific antibody to block the RNA-
NGA of the toxin is directly related to its ability to neu-
tralize Stx2-mediated HeLa cell death. Those antibodies
that were better in blocking the RNA-NGA of Stx2
were also better in neutralizing Stx2 mediated HeLa cell
death (Table 1 and Fig. 1). The Stx2A-specific HuMAbs
2F10, 3E9, and 5C12 were best in blocking the RNA-
NGA of Stx2 as well as protecting HeLa cells against
Stx2-mediated cytotoxicity. Furthermore, 5C12 was the
strongest antibody in neutralizing both RNA-NGA (Fig.
3) and HeLa cell death mediated by Stx2 (Table 1).
Those antibodies that neutralized RNA-NGA of the
toxin lesser than 2F10, 3E9, and 5C12 also neutralized
Stx2-mediated HeLa cell death lesser than these 3 anti-
bodies, and those that neutralized RNA-NGA poorly
(4H10, 5F2, 3A2, 6E6, 7F2 and 1G12) were similarly
weaker in protecting HeLa cells against the toxin-death.
The discrepancies between the present and an earlier
study [20] in grouping of the HuMAbs based on the
HeLa cell cytotoxicity neutralization abilities seem to be
related to inconsistencies in quantification of proteins
by ELISA in the previous study [20]. We utilized UV
spectrophotometry in the present study since we
observed that protein estimation by this method avoids
variations due to assay plates and reagents that occur in
ELISA and provides more accurate results.
However, with the exception of the best RNA-NGA
blocking antibodies (5C12 and 2F10), the efficacies of
antibody neutralization of RNA-NGA of Stx2 did not
correlate with their in vivo protective efficacies. The
HuMAbs 6D8 and 6B7 neutralized RNA-NGA of Stx2
moderately but failed to protect mice; 6B7 protected
only 20% of mice at the highest dose of 50 μg/mouse
against Stx2-death, and 6D8 failed to protect any mice
at that dose. In contrast, 6C3 which neutralized RNA-
NGA of Stx2 less effectively than 6D8 and 6B7 pro-
tected 100% mice at the same highest dose. At the 10
fold lower dose, 6C3 still protected 20% of mice whereas
6D8 and 6B7 did not protect any mice. The best RNA-
NGA neutralizing antibodies 5C12 and 2F10 protected
100% and 60% of mice, respectively, at the 10 fold lower
dose of 5 μg/mouse. These findings are in agreement
with our earlier studies which showed that only 5C12,
2F10, 3E9 and 6C3, and none of the other A subunit-
specific antibodies analyzed in the present study pro-
tected mice against Stx2 challenge [20]. The ability of
the weak RNA-NGA neutralizing antibody 6C3 to pro-
tect mice strongly against Stx2 challenge suggest that
neutralization of RNA-NGA of Stx2 by antibodies is not
the only mechanism by which A subunit-specific antibo-
dies can neutralize Stx2 in vivo. This argument is also
strengthened by the failure of the moderate RNA-NGA
neutralizing antibody 6B7 to protect any mouse.
Another moderate RNA-NGA neutralizing antibody
6D8 protected only 20% mice at 50 μg/mouse dose and
none at 5 μg/mouse dose.
It is not clear how RNA-NGA neutralizing activity of
5C12 neutralizes the toxicity of Stx2 for HeLa cells
since our recent studies have shown that 5C12 blocks
the retrograde transport of the toxin to TGN and ER,
and prevents the Stx2 A subunit from entering the cyto-
sol where it exerts its RNA-NGA [24]. It is possible that
as a consequence of blocking RNA-NGA, 5C12 may
mask the site of furin cleavage on the A subunit or
induce conformational changes in the toxin such that
the furin action on the A subunit is evaded, and there-
fore, the toxin remains intact and bound to Gb3 when
Figure 4 Percent survival of mice given intraperitoneally (IP)
50 and 5 μg of HuMAbs 5C12, 2F10, 6B7, 6D8 and 6C3
followed 4 h later with IP administration of a lethal Stx2 dose.
Mice in PBS control groups died within 2 days of Stx2 challenge.
Star (*) above the columns represents significant survival as
compared to that of PBS. At 50 μg, 5C12, 2F10 and 6C3 completely
protected mice against Stx2-mediated toxicosis and death. At the
same dose, the antibodies 6B7 and 6D8 protected 0% and 20%
mice, respectively. At the low dose of 5 μg, 5C12 was highly
protective since it protected all mice, and 2F10 was moderately
protective since it protected 60% of mice. At the same dose, the
antibody 6C3 showed low level protection (protected 20% of mice),
and the antibodies 6B7 and 6D8 failed to protect any mouse.
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inside the cell. Our studies have shown that the binding
of 5C12 with the toxin does seem to induce conforma-
tional changes in the toxin molecule since binding affi-
nity of Stx2 to the Gb3 receptor increases when Stx2 is
bound by 5C12 than when it is unbound [24]. We have
proposed that stronger binding of Stx2 with the Gb3 in
presence of 5C12 may induce it to follow the same
intracellular path as is followed by the Gb3 [24].
Although the intracellular passage of Gb3 is unknown,
it is possible that Gb3, like transferrin receptor and
some other host cell surface molecules, may be destined
to be recycled back to the cell surface. However, a clear
understanding of the mechanism by which 5C12 neutra-
lizes Stx2 in vitro awaits further studies. In vivo clear-
ance studies of 5C12/Stx2 immune complexes from our
laboratory have recently shown that 5C12/Stx2 com-
plexes are rapidly cleared from body, mostly by liver
(manuscript in preparation).
Furin mediated cleavage of Shigella toxin A subunit is
essential for efficient intoxication of cells [17]. Since
Stx1 is identical to the Shigella toxin except a single
amino acid change of serine at position 45 to a threo-
nine, furin should also be essential for efficient catalytic
activity of Stx1. However, Stx2 shares only 56% identity
with Shigella toxin (or Stx1) at amino acid level [25];
consequently slight protein folding differences among
these two Stx types make the catalytic site of the A sub-
unit accessible in intact Stx2 [5]. This suggests that
nicking of Stx2A by furin should not be essential for
efficient RNA-NGA of Stx2, and that both Stx2A and
Stx2A1 should have the same catalytic efficiency, as has
been shown for a Stx2 variant [26]. In the present study,
the holotoxin preparation consisted of the intact toxin
and some of the Stx2A1 and Stx2A2 fragments (Wes-
tern blot results, not shown). Such processing of Stx
during purification by bacterial proteases is common
and has been reported elsewhere [26]. However, pre-
sence of Stx2A1 does not affect its neutralization by
5C12 since 5C12 binds both Stx2A and Stx2A1 (Wes-
tern blot results, not shown).
Conclusion
In summary, the neutralization efficiency of the RNA-
NGA of Stx2 by A subunit-specific antibodies correlate
strongly with their abilities to protect HeLa cells against
Stx2-mediated toxicity but only the strongest RNA-NGA-
neutralizing antibodies correlate very well with both pro-
tecting HeLa cells and mice against Stx2 challenge.
Methods
Stx2
Stx2 was purified as described previously [27]. The Stx2
stock was dissolved at 50 μg/ml in phosphate buffered
saline (PBS), aliquoted and stored at -20°C.
Stx2-specific HuMAbs
Nineteen Stx2A-specific human monoclonal antibodies
(HuMAbs) (1G1, 2F10, 3E9, 5C12, 6H5, 6H7, 7C4, 9H9,
14C12, 4H10, 5E12, 6C3, 6D8, 6E6, 1G12, 3A2, 5F2,
6B7, and 7F2) and one Stx2B-specific HuMAb (5H8)
produced elsewhere [20] were included in the present
study. All antibodies were of human IgG1 isotype.
These antibodies were grouped as high, medium or low
neutralizing antibodies based on their efficacies to neu-
tralize Stx2 in a HeLa cell cytotoxicity assay [20]. The
antibodies were quantified by ELISA [20]. However, we
have observed that protein estimation by UV spectro-
photometry provides more accurate results since varia-
tions due to assay plates and reagents that occur in
ELISA are avoided. Since quantification by UV spectro-
photometry requires purified protein, the antibodies
were purified by protein A affinity chromatography, dia-
lyzed against PBS, quantified by UV spectrophotometry
(ND-1000 Spectrophotometer, Nanodrop), aliquoted,
and stored at -20°C. The HuMAbs were quantified every
time immediately before use in an experiment to ensure
that their concentrations did not change.
HeLa cell cytotoxicity assay
An in vitro HeLa cell cytotoxicity assay was performed to
evaluate the ability of protein A-purified 19 HuMAbs to
neutralize the cytotoxic effects of Stx2 as described else-
where [23], and to group the antibodies as high, medium
or low neutralizing. Briefly, Stx2 at 20 ng/ml concentration
(killed > 80% of HeLa cells) was preincubated with the
HuMAbs at 10.00 and 1.25 μg/ml for 1 h at 37°C in 5%
CO2, and then added to the HeLa cells. The plates were
incubated overnight at 37°C in 5% CO2. Dead cells were
removed by washing with PBS, and viable cells stained
with Crystal Violet. The absorbance was read at 690 nm,
and the percent neutralization of Stx2-mediated HeLa cell
cytotoxicity by the HuMAbs was calculated by the for-
mula: [(ODtoxin + HuMAb - ODtoxin only)/(ODno toxin -
ODtoxin only)] × 100, where the ODs included from the
wells containing toxin plus HuMAb (ODtoxin + HuMAb),
toxin only (ODtoxin only), and no toxin or cell culture med-
ium only (ODno toxin) [23]. The experiments were repeated
three times and each antibody dose was tested in duplicate
wells.
For statistical analysis, comparisons of the means of
neutralization rates (%) were made among 19 HuMAbs
at 3 different concentrations of antibodies using analysis
of variance (ANOVA) test. Pairwise multiple compari-
sons were then done using Fisher LSD Method. Resulting
p-values of less than 0.05 were considered significant.
In vitro translation in a rabbit reticulocyte lysate system
In vitro translation system utilizing rabbit reticulocyte
lysate [15] and biotinylated lysine tRNA (Transcend™
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tRNA) was used to measure RNA-NGA of holotoxin
Stx2. The RNA NGA site of the A subunit is accessible
in the intact holotoxin Stx2 [5]. All reagents, including
the Flexi rabbit reticulocyte lysate kit, were purchased
from Promega (Madison, WI). Protein translation condi-
tions were standardized by adjusting the concentrations
of each component, especially potassium, magnesium,
and transcend™ tRNA. The final translation reactions,
assembled in conical-bottom 96-well plates at a final
volume of 50 μl per sample, consisted of 10 μl of basic
components (Nuclease-free water, 2.5 M potassium
chloride, 25 mM magnesium acetate, 40 units/μl Rna-
sin®ribonuclease inhibitor, 1 mM complete amino acid,
transcend™ tRNA, and 1 mg/ml luciferase template
RNA), 24 μl of rabbit reticulocyte lysate, and 16 μl of
the samples (PBS or Stx2 or Stx2 plus HuMAbs).
To quantify inhibition of protein synthesis by Stx2, a
stock Stx2 solution was serially diluted (40 to 0.31 ng of
Stx2 in 16 μl volume) in PBS and tested in the rabbit
reticulocyte lysate for inhibition of translation of lucifer-
ase. A 16 μl aliquot of Stx2 was incubated with 24 μl of
reticulocyte lysate at room temperature (RT) for 30 min.
Ten μl of basic components were then added, and the
plates incubated for 1 h at 30°C in a waterbath. The
reaction was terminated by placing the plates on ice,
and the biotinylated luciferase analyzed by Western
blotting.
To investigate the ability of 19 Stx2A-specific
HuMAbs to neutralize the Stx2-mediated inhibition of
protein synthesis, a dose of 10 ng of Stx2 was selected
since this dose inhibited protein synthesis completely, as
determined from studies outlined above. Human IgG1
isotype (Sigma), and a HuMAb 5H8 against the B subu-
nit of Stx2, were included as controls. For these experi-
ments, 10 ng of Stx2 in 8 μl PBS were incubated with
93.7 ng of Stx2-specific HuMAbs in 8 μl PBS at RT for
30 min. The rest of the steps were same as described
above, and the translated luciferase protein was again
analyzed by Western blotting. The concentration of 93.7
ng utilized in these studies was based on a few dose
response studies conducted on selected antibodies to
determine an antibody dose that would strongly neutra-
lize the RNA-NGA of 10 ng Stx2.
Western blot analysis
The translated biotinylated luciferase was separated by
sodium dodecyl sulfate polyacrylamide gel electrophor-
esis (SDS-PAGE) under reducing conditions, and electro-
phoretically transferred to a PVDF membrane (Bio-Rad).
After washing with TBS-T (Tris-buffered saline, 0.05%
Tween® 20), the membrane was incubated at RT for 30
min with streptavidin-HRP conjugate (Promega, Madi-
son, WI) diluted 1:30,000 in TBS-T. After washing, the
membrane was incubated with a chemiluminescent
substrate (ECL plus western blotting detection system,
Amersham Biosciences), and exposed to Kodak BioMax
film (VWR international, Bridgeport, NJ) for 1-5 min.
The bands were scanned by Kodak Image Station
2000RT and their intensities analyzed with Kodak 1D
Image Analysis Software version 3.6.5 K2. Luciferase
band intensities in presence of antibodies were calculated
relative to the band intensities when Stx2 was absent.
Mouse protective efficacy
The mouse toxicity model was used to determine pro-
tective efficacy of selected HuMAbs against a lethal Stx2
dose in vivo as described elsewhere [23]. Groups of five
3- to 4-week-old female Swiss Webster mice (Taconic)
were injected intraperitoneally (IP) with 50 μg/mouse or
5 μg/mouse of antibody, or PBS, 4 hr prior to the IP
administration of a lethal Stx2 dose (75 ng/mouse in
200 μl of PBS). Mice were observed 3 or more times
daily for clinical signs and survival. All mouse proce-
dures were approved by the Tufts University Institu-
tional Animal Care and Use Committee.
For statistical analysis, the grouped survival data was
analyzed by applying Mantel-Cox test and performed
using PROC Frequency procedure of statistical software
SAS. Resulting p-values of less than 0.05 were consid-
ered significant.
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